Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)

被引：0
|
作者：
Ma, Cynthia
Bose, Ron
Gao, Feng
Freedman, Rachel
Telli, Melinda
Kimmick, Gretchen
Winer, Eric
Naughton, Michael
Goetz, Matthew
Russell, Christy
Tripathy, Debu
Cobleigh, Melody
Forero, Andres
Pluard, Timothy
Anders, Carey
Thomas, Shana
Anderson, Jill
Bumb, Caroline
Banks, Kimberly
Lanman, Richard
Bryce, Richard
Lalani, Alshad
Pfeifer, John
Hays, Daniel
Pegram, Mark
Blackwell, Kimberly
Bedard, Philippe
Al-Kateb, Hussam
Ellis, Matthew
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT011
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
    Ma, Cynthia X.
    Bose, Ron
    Gao, Feng
    Freedman, Rachel A.
    Pegram, Mark D.
    Blackwell, Kimberly
    Bedard, Philippe L.
    Hayes, Daniel F.
    Goetz, Matthew P.
    Niravath, Polly Ann
    Russell, Christy Ann
    Tripathy, Debu
    Cobleigh, Melody A.
    Forero, Andres
    Pluard, Timothy J.
    Anders, Carey K.
    Bumb, Caroline
    Naughton, Michael
    Al-Kateb, Hussam
    Ellis, Matthew James
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
    Ma, Cynthia X.
    Bose, Ron
    Gao, Feng
    Freedman, Rachel A.
    Telli, Melinda L.
    Kimmick, Gretchen
    Winer, Eric
    Naughton, Michael
    Goetz, Matthew P.
    Russell, Christy
    Tripathy, Debu
    Cobleigh, Melody
    Forero, Andres
    Pluard, Timothy J.
    Anders, Carey
    Niravath, Polly Ann
    Thomas, Shana
    Anderson, Jill
    Bumb, Caroline
    Banks, Kimberly C.
    Lanman, Richard B.
    Bryce, Richard
    Lalani, Alshad S.
    Pfeifer, John
    Hayes, Daniel F.
    Pegram, Mark
    Blackwell, Kimberly
    Bedard, Philippe L.
    Al-Kateb, Hussam
    Ellis, Matthew J. C.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5687 - 5695
  • [3] Circulating tumor DNA (ctDNA) mutation (mut) profile in relation to paboclicib (pal) efficacy in hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)
    Xi, Jing
    Bagegni, Nusayba
    Ademuyiwa, Foluso
    Frith, Ashley
    Suresh, Rama
    Roshal, Anna
    Rigden, Caron
    Hernandez-Aya, Leonel
    Peterson, Lindsay
    Opyrchal, Mateusz
    Clifton, Katherine
    Weilbaecher, Katherine
    Bose, Ron
    Ma, Cynthia
    CANCER RESEARCH, 2021, 81 (04)
  • [4] Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC)
    Hensing, Whitney L.
    Gerratana, Lorenzo
    Clifton, Katherine
    Velimirovic, Marko
    Shah, Ami
    D'Amico, Paolo
    Reduzzi, Carolina
    Zhang, Qiang
    Dai, Charles S.
    Bagegni, Nusayba A.
    Opyrchal, Mateusz
    Ademuyiwa, Foluso O.
    Ron, Bose
    Behdad, Amir
    Ma, Cynthia X.
    Bardia, Aditya
    Cristofanilli, Massimo
    Davis, Andrew A.
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Genetic heterogeneity profiling for HER2 positive single circulating tumor cell (CTC) in metastatic breast cancer (MBC) by application of DEPArray™ System and single cell DNA sequencing for HER2 positive single circulating tumor cell (CTC) in metastatic breast cancer (MBC) by application DEPArray™ system and single cell DNA sequencing
    Zhang, Qiang
    Gerratana, Lorenzo
    Pivarski, Kara L.
    Wang, Xinkun
    Ji, Zhe
    Stroup, Emily
    Vagia, Elena Vagia
    Davis, Andrew Adam Davis A. Adam
    Shah, Ami
    Kerby, Katy L.
    Flaum, Lisa Flaum
    Wehbe, Firas
    Zhang, Youbin
    Qiang, Wenan
    Behdad, Amir
    Gradishar, William
    Platanias, Leonidas
    Cristofanilli, Massimo
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Comparison of serum HER2 and CA15-3 in monitoring clinical tumor response in patients with HER2 positive metastatic breast cancer (MBC).
    Kong, SY
    Lee, DH
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 886S - 886S
  • [7] A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER.
    Ma, Cynthia X.
    Luo, Jingqin
    Freedman, Rachel A.
    Pluard, Timothy
    Nangia, Julie
    Lu, Janice
    Valdez-Albini, Frances
    Cobleigh, Melody
    Jones, Jason
    Lin, Nancy U.
    Winer, Eric
    Marcom, P. Kelly
    Thomas, Shana
    Anderson, Jill
    Haas, Brittney
    Hamann, Kimberly M.
    Bryce, Richard
    Lalani, Alshad S.
    Carey, Lisa
    Goetz, Matthew
    Gao, Feng
    Kimmick, Gretchen
    Pegram, Mark
    Ellis, Matthew J.
    Bose, Ron
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC)
    Austin, Laura Katherine
    Fortina, Paolo
    Sebisanovic, Dragan
    Siew, LaiMun
    Zapanta, Aubrey
    Talasaz, AmirAli
    Cristofanilli, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Trastuzumab emtansine in patients (pts) with HER2 mutation-positive (HER2mut) tumors: TAPISTRY study
    Kim, Jeong Eun
    Thomas, David
    Gadgeel, Shirish
    Corassa, Marcelo
    Tan, Tira J.
    Girda, Eugenia
    Richards, Donald
    Tejpar, Sabine
    Chen, David
    Fang, Junhan
    Patel, Sid
    Wilson, Timothy R.
    Barlesi, Fabrice
    CANCER RESEARCH, 2024, 84 (07)
12345